Name | Title | Contact Details |
---|
Recent changes in Medicare coding requirements have caused hospitals to suffer from lost revenues, penalties and forfeiture of reimbursements due to inadequate documentation. Founder Dr. Jon Elion, who earlier created the highly successful Heartlab imaging software, tackled this problem with an expert team. The result was the company`s premiere product, ChartWise:CDI, which is the first-to-market Computer-Assisted Clinical Documentation Improvement (CACDI) software system designed to improve precision in quality clinical documentation to support revenue assurance. In February 2014 ChartWise launched an upgraded system, ChartWise 2.0—redefining CDI with powerful new features and an advance new user interface. The program is easy for medical professionals to understand and use, has a light IT footprint, and offers hospitals a way to mitigate risk, maximize reimbursement, and gain insight into their medical documentation improvement efforts. No other program is as robust, or addresses the clinical documentation challenges, the way ChartWise 2.0 does.
America Service Group Inc. (ASG) through its subsidiaries Prison Health Services, Inc. (PHS), EMSA Limited Partnership (EMSA), and Correctional Health Services, LLC (CHS), contracts to provide and/or administer managed healthcare services to over 120
The UConn Health Center offers an impressive range of clinical services by more than 350 physicians in over 50 specialties on an outpatient basis and on an inpatient basis at John Dempsey Hospital.
Comphealth Associates is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.